BioSpace News Archive

Eyenuk, Inc. , a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, today announced strong business growth even as the COVID-19 pandemic is putting pressure on the healthcare systems worldwide.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that two abstracts for CA-4948, a novel, small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the European Hematology Association 2021 Virtual Congress (EHA),

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that two poster presentations of new clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, will be made at the European Hematology Association (EHA) Annual Congress meeting to be held virtually from June 9 - 17.

Amidst COVID-19, Mental Health Leaders, Policymakers Explore Innovations and Policy Solutions to Strengthen Access to Care for People Living with Serious Mental Illness

Longer term follow-up data from the pivotal CARTITUDE-1 study of cilta-cel in heavily pretreated patients with relapsed or refractory multiple myeloma The first presentation of data from the CARTITUDE-2 study of cilta-cel in earlier lines of multiple myeloma treatment

Executive leader brings industrial biotech expertise from Corbion, LS9 and Genencor to scale the Fine Mycelium™ technology platform.

The American College of Rheumatology announced the launch of a new white paper, “Rheumatic Diseases in America: Confronting the Challenge,” which provides an overview of the current health care challenges facing the rheumatic disease community and highlights the importance of receiving timely and appropriate treatment from a rheumatology health professional.

First Phase 3 data from the RELATIVITY-047 trial highlight clinical benefit of LAG-3 blocking antibody relatlimab – the company’s third distinct checkpoint inhibitor – in combination with nivolumab for patients with previously untreated unresectable or metastatic melanoma

Moffitt Cancer Center is honored to earn the No. 3 position on DiversityInc’s Top Hospitals and Health Systems for 2021.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced it will present findings from a new analysis of claims data from a cohort of patients who received RADICAVA® (edaravone) for the treatment of amyotrophic lateral sclerosis (ALS).